CloneID: B3
Antigen Long Description: The original antibody was generated by immunizing mice with the thio-LPA-KLH hapten.
Buffer Composition: PBS only.
Specificity Statement: This antibody binds lysophosphatidic acid (LPA), which is a bioactive lipid mediating multiple cellular responses including proliferation, differentiation, angiogenesis, motility, and protection from apoptosis in a variety of cell types. LPA is involved in the establishment and progression of cancer by providing a pro-growth tumor microenvironment and promoting angiogenesis. In addition, LPA has been implicated in neurotrauma, fibrosis, ocular diseases such as macular degeneration, and pain-related disorders.
Application Notes (Clone): The binding characterization of this antibody for different isoforms of LPA was done using ELISA. The original antibody binds LPA with a very high binding affinity of Kd= 1.4 pM. This antibody is capable of recognizing all the isoforms of LPS (12:0 LPA; 14:0 LPA; 16:0 LPA; 18:1 LPA; 18:2 LPA and 20:4 LPA). This antibody was reported to have an inhibitory effect on the LPA-stimulated migration of renal cell carcinoma (Caki-1) cells and also inhibit the release of pro-tumorigenic cytokines from tumor cells. This antibody could also inhibit tumor angiogenesis in vivo. In an in vitro mouse model of metastasis this antibody reduced tumor progression (US8604172). This antibody LPA and prevents it from interacting with its complement of receptors, and blocks LPA's effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death (PMID: 22819724). Blocking LPA signaling with the this antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury (PMID: 24576351).
English
Deutsch
